OBJECTIVES: There has been growing interest in the potential benefits arising from the use of medical diagnostic technologies, primarily due to possible reductions in resource use and time to diagnosis. The objective of this study was to provide an estimate of the potential financial implications resulting from the introduction of Simtomax®, a rapid point of care test, for the diagnosis of coeliac disease and IgA deficiency. The study, performed from the perspective of the UK NHS, aimed to demonstrate that the additional test acquisition costs would be offset by resource savings.  METHODS: A 1 year budget impact model was developed looking at the key financial drivers of diagnosing coeliac disease, based on the NICE pathway. This included the cost of blood tests and other contributing costs, including GP visits, nurse visits, paediatric outpatient visits for testing children and carriage. The model compares Simtomax®to the current diagnosis pathway which comprises of serological testing for IgA tissue transglutaminase (tTGA) and a possible IgA deficiency test, using ELISA laboratory testing. Costs were taken from national sources with the exception of carriage costs which were estimated by a clinician as a national source was not available.   RESULTS: Although the cost of acquiring Simtomax® was £22.51 greater than the cost of a tTGA test, an overall cost saving of approximately £40.14 per patient was achieved as a result of resource savings. The analysis estimated that the introduction of Simtomax® could result in cost savings of up to £5,932,885 per annum to the UK NHS.  CONCLUSIONS: The analysis suggests that the use of Simtomax® for the diagnosis of coeliac disease would be financially beneficial because it may result in decreased resource use and cost savings. Additionally, the time required for health care professionals to diagnose coeliac disease could be reduced meaning patients receive treatment faster.